Chardan Capital Issues Pessimistic Forecast for Century Therapeutics (NASDAQ:IPSC) Stock Price

Century Therapeutics (NASDAQ:IPSC) had its price target lowered by Chardan Capital from $11.00 to $7.00 in a report released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently issued reports on IPSC. Piper Sandler lowered their price objective on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a research report on Thursday, March 20th. Guggenheim cut their price target on shares of Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday, January 22nd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Century Therapeutics has a consensus rating of “Buy” and an average price target of $5.00.

Century Therapeutics Trading Up 0.2 %

Shares of IPSC stock opened at $0.56 on Monday. The firm has a market capitalization of $47.84 million, a P/E ratio of -0.30 and a beta of 1.75. Century Therapeutics has a 1 year low of $0.52 and a 1 year high of $4.43. The firm’s fifty day simple moving average is $0.72 and its 200 day simple moving average is $1.14.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The company had revenue of $4.18 million for the quarter, compared to the consensus estimate of $0.67 million. Equities research analysts anticipate that Century Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently made changes to their positions in the company. State Street Corp boosted its position in Century Therapeutics by 7.4% in the third quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after buying an additional 57,323 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Century Therapeutics in the third quarter valued at approximately $284,000. Barclays PLC raised its stake in shares of Century Therapeutics by 283.6% in the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after acquiring an additional 45,797 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Century Therapeutics by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock worth $1,656,000 after acquiring an additional 32,614 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Century Therapeutics by 257.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock worth $123,000 after acquiring an additional 51,664 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.